Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Deciphera Pharmaceuticals (DCPH) Tops Q2 EPS by 6c
August 4, 2022 7:18 AM EDTDeciphera Pharmaceuticals (NASDAQ: DCPH) reported Q2 EPS of ($0.60), $0.06 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $30.58 million.
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
... More